UK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic reaction shot and a drug to reverse the effects of opi
While Sandoz has emerged as the front-runner to get a generic version of GlaxoSmithKline’s respiratory blockbuster Advair to the US market, rival Hikma has not given up despite a major setb